Tag: exocrine pancreatic insufficiency epi therapeutics and diagnostics market growth

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Valued at Present and by 2029?

In recent years, the market size for diagnostics and therapeutics of exocrine pancreatic insufficiency (epi) has expanded significantly. Its growth is projected to accelerate from $5.69 billion in 2024 to $6.11 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The increase during the historic period can be credited to a larger incidence of related conditions, advancement in diagnostic instruments, progress in pharmaceuticals, and enhanced global access to healthcare.

The market size for therapeutics and diagnostics of exocrine pancreatic insufficiency (epi) is projected to experience robust expansion in the upcoming years, with expectations to escalate to “$8.21 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.7%. The market augmentation during the forecast period is expected to be driven by factors such as telemedicine and remote monitoring, artificial intelligence and data analytics, patient enlightenment and support, regulatory amendments and revising reimbursement policies. The forecast period can also expect to see trending elements including personalized treatment techniques, the invention of innovative therapies, minimally invasive diagnostic procedures, and collaborative care structures.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

#What Drivers Are Influencing Growth In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

The rise in diabetes cases is anticipated to boost the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market’s growth. Diabetes is a lasting metabolic disorder marked by elevated blood sugar levels (hyperglycemia) over an extended period, caused by the body failing to produce or effectively utilize insulin. EPI treatment, encompassing pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption for individuals with diabetes and EPI, as well as better glycemic control. For example, the UK’s National Health Service (NHS England) reported in June 2024 that the count of individuals recognized as pre-diabetic rose to 3,615,330 in 2023, an 18% growth from 3,065,825 in 2022. Moreover, among those below 40, there was a nearly 25% increase in cases, from 173,166 in 2022 to 216,440 in 2023. Hence, the growing prevalence of diabetes is fueling the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

What Long-Term Trends Are Likely To Affect The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Prominent companies in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry are utilizing strategic partnerships to boost technology assimilation and broaden their market influence. Such partnerships refer to a synergy between two or more entities aimed at pooling resources, skills, and efforts toward achieving shared targets or objectives. To illustrate, Codexis, Inc., a protein engineering firm based in the US, and Nestlé Health Science, a Swiss nutrition science firm, reported preliminary results in February 2023 from their Phase 1 clinical trial on CDX-7108. This product under investigation targets treatment for EPI. The outcomes of this Phase 1 trial set the stage for subsequent trials that may enhance treatment solutions for patients affected by EPI substantially.

Which Companies Play A Key Role In The Development Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

What Are The Key Regional Developments Shaping The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth Performance Trended Historically, And What Lies Ahead?

The market size of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics has seen significant growth in the past few years. From 2024’s valuation of $5.69 billion, it’s projected to increase to $6.11 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.3%. Historical growth in this sector can be credited to factors such as the rise in associated disorders, enhancements in diagnostic techniques, advancement in pharmaceuticals, and growing accessibility to global healthcare services.

In the upcoming years, the market size for exocrine pancreatic insufficiency (epi) therapeutics and diagnostics is projected to see robust growth. It is predicted to hit $8.21 billion in 2029, with a compound annual growth rate (CAGR) of 7.7%. This projected growth during the forecast period can be linked to factors such as telemedicine and remote monitoring, data analytics and AI, patient education and support, and changes in regulatory and reimbursement policies. The period is also expected to see major trends such as personalized therapies, the development of new treatments, minimally invasive diagnostics, and collaborative care models.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What Are the Core Growth Drivers Propelling the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Forward?

The escalation in the count of individuals suffering from diabetes is anticipated to fuel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Describing diabetes, it’s a persistent metabolic condition portrayed by raised blood sugar levels, or hyperglycemia, sustained over an extended time. The problem arises from the body’s incapacity to generate a sufficient amount of insulin or effectively utilize the insulin it does produce. EPI treatment, employing pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption in patients with diabetes and EPI. It can also boost glycemic control in individuals battling diabetes. For instance, according to The National Health Service (NHS England) in June 2024, a UK government-funded healthcare system, reported an 18% spike in the number of individuals identified by the NHS in England as pre-diabetics, from 3,065,825 in 2022 to 3,615,330 in 2023. Also, in individuals below 40, cases rocketed around 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Consequently, this rising count of people grappling with diabetes is sparking the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

What Segment Types Define the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Structure?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Emerging Trends that Are Influencing theExocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Industry Evolution?

Major firms active in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics sector are embracing a strategic partnership model to boost technological synergy and broaden their market influence. A strategic partnership usually signifies a cooperative interaction between multiple organizations, pooling their resources, proficiency and work to fulfill shared goals. For example, in February 2023, Codexis, Inc., a protein engineering organization based in the US, and Nestlé Health Science, a Switzerland-based nutritional science firm, released interim findings from their Phase 1 clinical trial of CDX-7108, an experimental therapy for EPI treatment. The conclusions of this Phase 1 trial set the stage for subsequent research that could majorly enhance the treatment alternatives for EPI patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

What Is the Definition of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics refer to treating a condition in which the pancreas does not produce enough digestive enzymes required for the proper breakdown and absorption of nutrients from food in the small intestine. EPI diagnostics and therapeutics play a crucial role in diagnosing and managing exocrine pancreatic insufficiency, helping individuals with EPI achieve better nutrient absorption and overall well-being.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth in 2025?

The market size for therapeutics and diagnostics relating to exocrine pancreatic insufficiency (EPI) has seen substantial growth recently. It’s anticipated that the market will increase from $5.69 billion in 2024 to $6.17 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.4%. This previous period of growth can be associated with a spike in pre-existing conditions, progression in diagnostic technologies, advancements in pharmaceuticals, and an increase in global healthcare accessibility.

What Is the Forecast for the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size Through 2029?

Anticipated to experience robust expansion in the coming years, the market for therapeutics and diagnostics of exocrine pancreatic insufficiency (EPI) is projected to reach a valuation of $8.32 billion in 2029, growing at a compound annual growth rate (CAGR) of 7.8%. Factors attributing to the predicted growth during the forecast period include advancements in telemedicine and remote tracking, data analysis and artificial intelligence, patient instruction and support, along with regulatory amendments and reimbursement policies. Noteworthy trends during this forecast period encompass personalized treatment strategies, the invention of innovative therapies, minimally invasive diagnostic tools, and collaborative care paradigms.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What are the Key Market Players in Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market and How They’re Evolving?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

What Are the Primary Growth Drivers in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is expected to be driven by the escalating cases of diabetes. Diabetes is a chronic metabolic disorder typified by enduring hyperglycemia due to insufficient insulin production or ineffective utilization of produced insulin. Therapeutic interventions for EPI, such as pancreatic enzyme replacement therapy (PERT), have shown to be beneficial in boosting nutrient absorption and enhancing glycemic control in diabetic patients. For instance, The National Health Service (NHS England) reported that in June 2024, the prevalence of individuals identified with pre-diabetes in England rose by 18% from 3,065,825 in 2022 to 3,615,330 in 2023. In individuals below 40 years, the count increased by nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Therefore, the rising diabetic population is anticipated to bolster the growth of the EPI therapeutics and diagnostics market. The EPI therapeutics and diagnostics market is set for growth, driven by an upsurge in gastrointestinal diseases. These diseases impact the gastrointestinal tract that includes digestion-related organs. EPI therapeutics and diagnostics are vital in the management of these diseases, as they help in replenishing the deficient enzymes and facilitate proper digestion. For example, in June 2023, Crohn’s and Colitis Canada noted that over 322,600 Canadians, representing about 0.82% of the nation’s population, were living with inflammatory bowel diseases (IBD) in 2023. As IBD prevalence continues, the estimate is that by 2035, nearly 470,000 Canadians or approximately 1.1% of the population (1 in every 91 people) will be affected. Consequently, the spike in gastrointestinal diseases is expected to fuel the market growth for EPI therapeutics and diagnostics.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp

What Are the Leading Segments in the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Industry?

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

What Are the Key Market Trends in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Industry?

Leading firms in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are strategically partnering to enhance technological integration and broaden market penetration. This sort of strategic collaboration typically involves multiple organizations combining their resources, knowledge, and initiatives for shared objectives. For instance, Codexis, Inc., a protein engineering enterprise based in the United States, and Nestlé Health Science, a company dedicated to the science of nutrition from Switzerland, disclosed preliminary results from their Phase 1 clinical trial of CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI), in February 2023. These Phase 1 trial results open the door for more research that could dramatically improve therapy avenues for patients with EPI.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

What Is the Regional Outlook for the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992

This Report Delivers Insight On:

1. How big is the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market, and how is it changing globally?

2. Who are the major companies in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market, and how are they performing?

3. What are the key opportunities and risks in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market right now?

4. Which products or customer segments are growing the most in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?

5. What factors are helping or slowing down the growth of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theExocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

A rise in diabetes cases is believed to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes, a chronic metabolic disorder, is marked by elevated blood sugar levels over an extended period due to the body’s inefficiency in producing or using insulin. EPI therapy, specifically pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption and glycemic control in diabetes and EPI patients. For instance, as per NHS England in June 2024, the number of pre-diabetes individuals identified by NHS England in 2023 stood at 3,615,330, an 18% increase from 2022’s 3,065,825. Among people under 40, the cases rose by nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Hence, the escalating number of those suffering from diabetes is boosting the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market’s growth. Growth in gastrointestinal disorders is anticipated to drive the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. These disorders affect the gastrointestinal tract, responsible for the digestion process. Here, EPI therapeutics and diagnostics come into play by addressing the enzyme deficiency causing these disorders and assisting digestion. For instance, Crohn’s and Colitis Canada reported in June 2023 that more than 322,600 Canadians, approx 0.82% of the population, were living with inflammatory bowel diseases (IBD) in 2023. As IBD prevalence continues, around 470,000 Canadians, or roughly 1.1% of the population (1 in every 91 people), are expected to be inflicted with IBD by 2035. Hence, increasing gastrointestinal diseases will, in turn, spur the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

#What Are the Key Projections for the CAGR of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market From 2025 to 2034?

There has been a significant increase in the market size of therapeutics and diagnostics for exocrine pancreatic insufficiency (EPI) in the past few years. The market, which stood at $5.69 billion in 2024, is expected to reach $6.17 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.4%. The upwards trend in the past can be linked to factors such as a rise in the incidence of underlying conditions, improvements in diagnostic technologies, advancements in pharmaceuticals, and increased accessibility to global healthcare.

In the forthcoming years, it is anticipated that the market size of exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics will witness a robust growth. The market is projected to ascend to $8.32 billion in 2029, with a compound annual growth rate (CAGR) of 7.8%. This promising growth during the forecast period can be credited to aspects such as telemedicine and remote monitoring, data analytics and ai, patient enlightenment and backing, regulatory modifications and compensation policies. The forecast period is set to see prime trends like customised treatment approaches, the emergence of novel therapies, minimally invasive diagnostics, and cooperative care models.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992

Which Upcoming Market Trends and Innovations Are Set to Influence theExocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market’s Path Forward?

Leading firms in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are employing a strategy of strategic alliances to bolster technology sharing and widen their market presence. Strategic partnerships are generally an alliance between two or more organizations, pooling their resources, skills, and energies towards shared targets. For example, Codexis, Inc., a protein engineering entity based in the US, and Nestlé Health Science, a Swiss nutrition science organization, revealed preliminary findings in February 2023 from their Phase 1 clinical research of CDX-7108 – a therapeutic under investigation for EPI treatment. This trial’s outcomes set the stage for subsequent researches that have the potential to markedly enhance EPI treatment choices for patients.

Who Are the Dominant Market Players Pushing the Boundaries of theExocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

What Are the Core Segments of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, and How Do They Contribute to Growth?

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp

What Regions Are Dominating the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2025, By The Business Research Company:

Gastric Volvulus Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

Inflammatory Bowel Disease Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Digestive Health Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digestive-health-supplements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics market grown over the years?

In recent times, the market size for therapeutics and diagnostics of exocrine pancreatic insufficiency (EPI) has seen significant growth. The market is projected to increase from a value of $5.69 billion in 2024 to $6.17 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.4%. The expansion during the historical period is due to factors such as increased incidence of root causes, advancements in diagnostic technology, evolution in pharmaceutical techniques, and improved global healthcare accessibility.

What Is the forecasted market size and growth rate for the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?

The market for therapeutics and diagnostics related to exocrine pancreatic insufficiency (EPI) is projected to experience substantial growth in the coming years. The market size is anticipated to rise to $8.32 billion by 2029, with a compound annual growth rate (CAGR) of 7.8%. The upswing during the forecast period can be linked to developments in telemedicine and remote monitoring, data analytics and AI, as well as improvements in patient education/support and changes in regulatory and reimbursement policies. Key trends envisioned for this period encompass personalized treatment strategies, the introduction of new therapies, less invasive diagnostic methods, and cooperative care models.

Get your exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report here!

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

What are the major factors driving growth in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?

As diabetes prevalence rises, it’s predicted to fuel advancements in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes is a long-term metabolic disorder associated with elevated blood sugar levels (hyperglycemia) over an extended duration. This is primarily due to the body not producing sufficient insulin or not being able to effectively utilize the insulin it does create. EPI therapy, which incorporates pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption in diabetic patients and those with EPI and can also better control blood sugar levels in diabetic individuals. For instance, The National Health Service (NHS England) reported in June 2024 that the number of individuals in England identified as pre-diabetic by the NHS had risen by 18% to 3,615,330 in 2023, up from 3,065,825 in 2022. Notably, among the under-40 age group, the number increased almost 25%, up from 173,166 in 2022 to 216,440 in 2023. Therefore, the rising diabetes prevalence is stimulating the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market’s growth. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Driver: An Uptick in Gastrointestinal Disorders Expected to Boost Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics

What key areas define the segmentation of the global exocrine pancreatic insufficiency (epi) therapeutics and diagnostics Market?

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What are the top market players propelling the growth of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics industry?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

What are the key trends shaping the future of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?

Key corporations in the Exocrine Pancreatic Insufficiency (EPI) therapeutics and diagnostics market are leveraging strategic partnerships to augment tech integration and widen their market presence. Strategic partnerships often involve two or more organizations pooling their resources, competencies, and endeavors to realize shared aims. For instance, in February 2023, a noteworthy partnership was formed between Codexis, Inc., a US-based protein engineering company, and Nestlé Health Science, a nutrition science company from Switzerland. They released preliminary results from their initial clinical trial of CDX-7108, a therapy under investigation for the treatment of EPI. These phase 1 trial findings could lay the foundation for additional studies that may considerably enhance treatment choices for EPI patients.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992

What regions are dominating the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market growth?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Gastric Volvulus Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

Inflammatory Bowel Disease Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Digestive Health Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digestive-health-supplements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Analyzing the Growth Rate of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market: What’s the Expected CAGR for the Next Decade?

The market size for EPI (exocrine pancreatic insufficiency) therapeutics and diagnostics has seen robust growth of late. The market is projected to increase from a value of $5.69 billion in 2024 to $6.17 billion in 2025, representing a compound annual growth rate (CAGR) of 8.4%. Factors such as higher incidence of underlying conditions, progress in diagnostic instrument technology, advancements in pharmaceuticals, and increased access to global healthcare services have all contributed to the growth during the historical period.

Anticipated to witness robust growth in the forthcoming years, the market size for therapeutics and diagnostics related to exocrine pancreatic insufficiency (EPI) is projected to rise to $8.32 billion by 2029 at a compound annual growth rate (CAGR) of 7.8%. Factors propelling growth during the forecast period include advancements in telemedicine and remote monitoring, data analytics and artificial intelligence, patient education and support, in addition to shifts in regulatory policies and reimbursement guidelines. The period is also expected to usher in major market trends such as customized treatment strategies, the inception of new therapies, minimally intrusive diagnostics, and cooperative care models.

Which Primary Drivers Are Supporting the Continued Expansion of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics Market?

The uptick in diabetes diagnoses is anticipated to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes, a chronic metabolic disorder marked by long-term hyperglycemia, results from the body’s inability to sufficiently produce insulin or effectively utilize the insulin it does produce. Treating EPI with pancreatic enzyme replacement therapy (PERT) improves nutrient absorption in diabetic individuals with EPI and enhances their glycemic control. The National Health Service (NHS England), a UK-based publicly funded healthcare organization, revealed that in June 2024, the number of people in England with pre-diabetes identified by the NHS had risen to 3,615,330 by 2023, an 18% rise from 3,065,825 in 2022. Likewise, among those below 40, cases spiked nearly 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Therefore, the swelling number of diabetic individuals is spurring the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. The escalating incidence of gastrointestinal disorders is predicted to stimulate the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market’s growth. Gastrointestinal diseases, comprising several health conditions that impact the digestive system, are prevalent. Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics are vital for managing these gastrointestinal diseases by substituting deficient enzymes and thereby aiding digestion. As per Crohn’s and Colitis Canada, a non-profit organization, more than 322,600 Canadians were believed to be living with inflammatory bowel diseases (IBD) in June 2023, roughly 0.82% of the populace. Predictions suggest that the prevalence of IBD will continue and approximately 470,000 Canadians or about 1.1% of the population or 1 in 91 people will be living with IBD by 2035. Therefore, the increasing occurrence of gastrointestinal diseases is likely to stimulate the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market’s growth.

Explore Comprehensive Insights Into The Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What Are the Leading Organizations Impacting the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market’s Growth?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are:

• Pfizer Inc._x000D_

• Merck & Co. Inc._x000D_

• Janssen Pharmaceuticals Inc._x000D_

• AbbVie Inc._x000D_

• Novartis AG_x000D_

What Are the Most Prominent Trends Driving Change in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Key players in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are opting for strategic partnerships for technological enhancement and to extend their market influence. A strategic partnership refers to a cooperative tie-up between two or more entities pooling their resources, know-how, and endeavors to attain shared goals. An example of this occurred in February 2023 when Codexis, Inc., a protein engineering company from the US, and Nestlé Health Science, a Swiss nutrition science company, unveiled preliminary results from their Phase 1 clinical examination of CDX-7108, a potential therapy for EPI. The findings from this Phase 1 study lay the groundwork for potential future studies, which could significantly enrich the therapeutic choices for EPI patients.

Secure Your Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Which Segments Play a Crucial Role in the Expansion of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

What Regions Are Leading the Charge in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Does the Definition of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Include?

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics refer to treating a condition in which the pancreas does not produce enough digestive enzymes required for the proper breakdown and absorption of nutrients from food in the small intestine. EPI diagnostics and therapeutics play a crucial role in diagnosing and managing exocrine pancreatic insufficiency, helping individuals with EPI achieve better nutrient absorption and overall well-being.

Browse Through More Similar Reports By The Business Research Company:

Gastric Volvulus Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

Inflammatory Bowel Disease Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Digestive Health Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digestive-health-supplements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: